Medifocus, Inc. to Present at the SeeThruEquity 3rd Annual Microcap Investor Conference and the Third Annual Marcum MicroCap Conference
Submitted by Medifocus Inc. on Tuesday, 05/27/2014
COLUMBIA, Md. and Toronto, ON- May 27, 2014 – Medifocus, Inc. (OTCQX: MDFZF and TSXV: MFS) announced today that, to increase investor’s awareness and Medifocus, Inc.’s visibility in the U.S. capital markets, it will present at both the SeeThruEquity 3rd Annual Microcap Investor Conference and the Third Annual Marcum MicroCap Conference in New York City.
On Wednesday, May 28, 2014 at the SeeThruEquity 3rd Annual Microcap Investor Conference held at the Convene in Grand Central, Medifocus, Inc.’s Chief Executive Officer, Dr. Augustine Cheung, is scheduled to present at 1:00 pm ET in the Park Hub and will provide an overview of Medifocus, Inc.’s business and growth strategy to investors.
On Thursday, May 29, John Mon, Chief Operating Officer of Medifocus, Inc., will be a featured presenter at the 3rd Annual Marcum MicroCap Conference at the Grand Hyatt Hotel. The Company’s presentation is scheduled to begin at 2:30 p.m. ET.
Management will also be available to meet with members of the investment community during one-on-one sessions being held at the conferences.
Medifocus owns two fully developed technology platforms with comprehensive United States and international patent protection: (i) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The United States Food and Drugs Administration (FDA) approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. Medifocus’ APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, has received approval from the FDA and Health Canada to conduct the pivotal Phase III clinical trials. Medifocus believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers.
www.medifocusinc.com, www.prolieve.com and http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.
This news release contains “forward-looking statements” and “forward-looking information”, which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect to the benefit to Medifocus’ future growth resulting from the acquisition of additional intellectual property rights, additional treatment possibilities and the expectation that sales from Prolieve® may accelerate as a consequence. Forward-looking statements are frequently characterized by words such as “plan,” “expect,” “project,” “intend,” “believe,” “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Company Relations: John Mon, COO, Medifocus, Inc. Tel: 410-290-5734 email@example.com